Latest Information Update: 04 Feb 2016
At a glance
- Originator Cell-Therapy Technology Institute
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Glioma
Most Recent Events
- 04 Feb 2016 CyTIX 01 is available for licensing as of 04 Feb 2016. http://www.cytix.net/
- 01 Nov 2004 Phae-I/II clinical trials in Glioma in Japan (Intradermal)
- 31 Dec 2001 Phase-I clinical trials in Glioma in Japan (Intradermal)